Tharimmune Appoints COO, CEO Becomes Chairman, Regains Nasdaq Compliance
summarizeSummary
Tharimmune, Inc. appointed Angela Radkowski as Chief Operating Officer, elected CEO Mark Wendland as Chairman of the Board, and announced it has regained compliance with Nasdaq's board independence rule.
check_boxKey Events
-
Chief Operating Officer Appointed
Angela Dominy Radkowski was appointed Chief Operating Officer, effective February 5, 2026. She brings experience from DRW Holdings LLC and Citadel LLC, with an annual base salary of $300,000 and a target bonus of $100,000, plus equity eligibility. This hire is strategic for the company's Canton Network infrastructure strategy.
-
Board Leadership Update
Mark Wendland, current Chief Executive Officer, was elected Chairman of the Board, effective February 5, 2026. Vincent LoPriore transitions from Chairman to a Board member. New committee appointments were also made, including Gary Stetz as Chair of the Audit and Compensation Committees, and Clay Kahler as Chair of the Nominating & Corporate Governance Committee.
-
Regains Nasdaq Board Independence Compliance
The company received notification on February 2, 2026, that it has regained compliance with Nasdaq Listing Rule 5605(b)(1) regarding board independence. This follows the election of two independent directors on January 30, 2026, resolving a deficiency previously reported on January 9, 2026.
auto_awesomeAnalysis
This 8-K details significant leadership and governance changes at Tharimmune, Inc., aligning with its recent strategic shift towards the Canton Network. The appointment of Angela Radkowski as Chief Operating Officer, with her background in scaling complex financial systems at DRW Holdings and Citadel, is a key hire to drive the company's institutional platform expansion. Concurrently, CEO Mark Wendland's election as Chairman of the Board centralizes leadership. Importantly, the company has also regained compliance with Nasdaq's board independence rule, resolving a previously identified deficiency and ensuring continued listing. These moves collectively strengthen the company's operational and governance structure as it pursues its digital asset strategy.
At the time of this filing, THAR was trading at $4.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $155.4M. The 52-week trading range was $0.95 to $9.08. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.